Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy

被引:12
作者
Eshuis, Emma J. [1 ,2 ]
Stokkers, Pieter C. F. [2 ]
Bemelman, Willem A. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
关键词
biologic therapy; clinical remission; Crohn's disease; decision-making; ileocecal disease activity; ileocolic resection; INFLAMMATORY-BOWEL-DISEASE; OPEN ILEOCOLIC RESECTION; QUALITY-OF-LIFE; LONG-TERM OUTCOMES; INFLIXIMAB MAINTENANCE; THERAPY; ADALIMUMAB; REMISSION; IMMUNOSUPPRESSION; IMMUNOMODULATORS;
D O I
10.1586/EGH.10.3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Ileocecal Crohn's disease (CD) can be treated medically as well as surgically. Both treatment modalities have been improved markedly in the last two decades, making CD more manageable. However, multidisciplinary research, addressing issues such as timing of surgery or medical treatment versus surgery, is scarce. Particularly in limited ileocecal CD, ileocolic resection might be a good alternative to long-term medical therapy. This review discusses the evidence on medical and surgical treatment options for ileocecal CD. It provides an aid in decision-making by discussing a treatment algorithm that can be used until further evidence on treatment is available.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 64 条
[1]
Timing of surgery in Crohn's disease:: A key issue in the management [J].
Alos, Rafael ;
Hinojosa, Joaquin .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (36) :5532-5539
[2]
Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? [J].
Andrews, J. M. ;
Travis, S. P. L. ;
Gibson, P. R. ;
Gasche, C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (05) :459-469
[3]
[Anonymous], COCHRANE DATABASE SY
[4]
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients [J].
Appau, Kweku A. ;
Fazio, Victor W. ;
Shen, Bo ;
Church, James M. ;
Lashner, Bret ;
Remzi, Feza ;
Brzezinski, Aaron ;
Strong, Scott A. ;
Hammel, Jeffrey ;
Kiran, Ravi P. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (10) :1738-1744
[5]
Early versus late surgery for ileo-caecal Crohn's disease [J].
Aratari, A. ;
Papi, C. ;
Leandro, G. ;
Viscido, A. ;
Capurso, L. ;
Caprilli, R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) :1303-1312
[6]
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[7]
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study [J].
Beaugerie, Laurent ;
Brousse, Nicole ;
Bouvier, Anne Marie ;
Colombel, Jean Frederic ;
Lemann, Marc ;
Cosnes, Jacques ;
Hebuterne, Xavier ;
Cortot, Antoine ;
Bouhnik, Yoram ;
Gendre, Jean Pierre ;
Simon, Tabassome ;
Maynadie, Marc ;
Hermine, Olivier ;
Faivre, Jean ;
Carrat, Fabrice .
LANCET, 2009, 374 (9701) :1617-1625
[8]
Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis [J].
Bernklev, T ;
Jahnsen, J ;
Schulz, T ;
Sauar, J ;
Lygren, I ;
Henriksen, M ;
Stray, N ;
Kjellevold, O ;
Aadland, E ;
Vatn, M ;
Moum, B .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (10) :1037-1045
[9]
Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data [J].
Bodger, K. ;
Kikuchi, T. ;
Hughes, D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) :265-274
[10]
A CONTROLLED DOUBLE-BLIND-STUDY OF AZATHIOPRINE IN THE MANAGEMENT OF CROHNS-DISEASE [J].
CANDY, S ;
WRIGHT, J ;
GERBER, M ;
ADAMS, G ;
GERIG, M ;
GOODMAN, R .
GUT, 1995, 37 (05) :674-678